Quality Care - everyone, everytime
 

6.6 Drugs affecting bone metabolism

NICE TA160 Osteoporosis - primary prevention Jan 2011

6.6.1 Calcitonin and parathyroid

  CALCITONIN Injection (Miacalcic) Intra-nasal formulations withdrawn
     

6.6.2 Bisphosphonates and other drugs affecting bone metabolism

1st ALENDRONATE (Weekly)
1st ETIDRONATE DISODIUM
1st DIDRONEL PMO
2nd RISEDRONATE (Weekly)
2nd STRONTIUM RANELATE
    NICE TA161 Osteoporosis - secondary prevention including strontium ranelate Jan 2011
  DISODIUM PAMIDRONATE (Yellow)
  IBANDRONIC ACID (Bonviva) Tablet (Yellow), Injection
  ZOLEDRONIC ACID (Yellow)
  DENOSUMAB
    NICE TA204 Denosumab for the prevention of osteoporotic fractures in postmenopausal women Oct 2010
    NICE TA265 Bone metastases from solid tumours - denosumab Oct 2012
     

 

Related pages

Keep up to date with the latest Trust News

Our Performance

To see our latest performance and financial report click here.

Tell Us Your Views

Click here to find out how you can feedback to us about your experiences, along with how to raise any concerns, complaints or questions.